Patents by Inventor Hendrik Jan Van Ooijen
Hendrik Jan Van Ooijen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230260595Abstract: A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of NFkB cellular signaling pathway target genes.Type: ApplicationFiled: September 14, 2022Publication date: August 17, 2023Applicant: InnoSIGN B.V.Inventor: Hendrik Jan VAN OOIJEN
-
Patent number: 11640845Abstract: A bioinformatics method for determining a risk score that indicates a risk that a subject will experience a negative clinical event within a certain period of time. The risk score is based on a combination of activities of two or more cellular signaling pathways in a subject, such as a human, wherein the specific cellular signaling pathways are the PI3K pathway and one or more of a Wnt pathway, an ER pathway, and an HH pathway. The invention also includes an apparatus with a digital processor configured to perform such a method, to a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and to a computer program comprising program code means for causing a digital processing device to perform such a method. The invention achieves advanced prognosis of negative clinical events, for example, disease progression, recurrence, development of metastasis, or even death.Type: GrantFiled: October 26, 2015Date of Patent: May 2, 2023Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Hendrik Jan Van Ooijen, Wilhelmus Franciscus Johannes Verhaegh, Anne Godefrida Catharina Van Brussel, Janneke Wrobel, Robert Van Gog
-
Publication number: 20230105263Abstract: The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.Type: ApplicationFiled: August 24, 2022Publication date: April 6, 2023Applicant: InnoSIGN B.V.Inventors: WILHELMUS FRANCISCUS JOHANNES VERHAEGH, ANJA VAN DE STOLPE, HENDRIK JAN VAN OOIJEN, KALYANA CHAKRAVARTHI DULLA, MARCIA ALVES DE INDA, RALF HOFFMAN
-
Patent number: 11610644Abstract: A bioinformatics method for determining a risk score that indicates a risk that a subject, in particular a human, will experience a negative clinical event within a certain period of time. The risk score is based on a unique combination of activities of two or more cellular signaling pathways in a subject, wherein the selected cellular signaling pathways are the TGF-? pathway and one or more of a PI3K pathway, a Wnt pathway, an ER pathway, and an HH pathway. The invention includes an apparatus with a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method.Type: GrantFiled: October 26, 2015Date of Patent: March 21, 2023Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Hendrik Jan Van Ooijen, Anne Godefrida Catharina Van Brussel, Jenneke Wrobel, Dianne Arnoldina Margaretha Wilhelmina Van Strijp, Robert Van Gog
-
Publication number: 20230071390Abstract: The present invention relates to a computer-implemented method for inferring activity of a PR cellular signaling pathway in a subject based on expression levels of three or more target genes of the PR cellular signaling pathway measured in a sample of the subject. The present invention further relates to an apparatus, to a non-transitory storage medium, and to a computer program for inferring activity of a PR cellular signaling pathway in a subject. The present invention further relates to a kit for measuring expression levels of three or more target genes of the PR cellular signaling pathway in a sample of a subject, to a kit for inferring activity of a PR cellular signaling pathway in a subject, and to the use of such kits in performing the method.Type: ApplicationFiled: November 12, 2020Publication date: March 9, 2023Applicant: InnoSIGN B.V.Inventors: Márcia Alves De Inda, Anja Van De Stolpe, Hendrik Jan Van Ooijen
-
Publication number: 20230030858Abstract: The present application mainly relates to specific methods for inferring activity of a cellular signaling pathway in tissue and/or cells of a medical subject based at least on expression levels of one or more target gene(s) of the cellular signaling pathway measured in an extracted sample of the tissue and/or cells of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.Type: ApplicationFiled: April 6, 2022Publication date: February 2, 2023Applicant: InnoSIGN B.V.Inventors: Hendrik Jan VAN OOIJEN, Wilhelmus Franciscus Johannes VERHAEGH, Paul Arnold VAN DE WIEL
-
Patent number: 11567089Abstract: The present invention relates to clinical decision support systems. In detail, the present invention relates to a method for determining the initial fibrinogen concentration in a biological sample, to the use of fibrinogen added to a biological sample in at least one predetermined concentration, to a device for determining the initial fibrinogen concentration in a biological sample, to a computer program comprising program code means for causing a computer to carry out at least several steps of the method according to the invention, to a computer readable non-transitory storage medium containing instructions for carrying out at least some steps of the method according to the invention, and to a kit for determining the initial fibrinogen concentration in a biological sample.Type: GrantFiled: December 18, 2015Date of Patent: January 31, 2023Assignee: Koninklijke Philips N.V.Inventors: Hendrik Jan Van Ooijen, Bart Jacob Bakker, Rene Van Den Ham
-
Patent number: 11450409Abstract: A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of NFkB cellular signaling pathway target genes.Type: GrantFiled: August 12, 2016Date of Patent: September 20, 2022Assignee: InnoSIGN B.V.Inventor: Hendrik Jan Van Ooijen
-
Patent number: 11443831Abstract: The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.Type: GrantFiled: July 19, 2012Date of Patent: September 13, 2022Assignee: InnoSIGN B.V.Inventors: Wilhelmus Franciscus Johannes Verhaegh, Anja Van De Stolpe, Hendrik Jan Van Ooijen, Kalyana Chakravarthi Dulla, Marcia Alves De Inda, Ralf Hoffmann
-
Publication number: 20220259666Abstract: The present invention relates to a method comprising inferring activity of a PI3K cellular signaling pathway in a tissue and/or cells and/or a body fluid of a medical subject based at least on expression levels of one or more target gene(s) of the PI3K cellular signaling pathway measured in an extracted sample of the tissue and/or the cells and/or the body fluid of the medical subject. The present invention further relates to an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method.Type: ApplicationFiled: January 17, 2022Publication date: August 18, 2022Inventors: Hendrik Jan VAN OOIJEN, Wilhelmus Franciscus Johannes VERHAEGH, Anja VAN DE STOLPE
-
Patent number: 11332271Abstract: The invention relates to a filling device (2) for filling a holder with vulnerable products, for instance apples, and a method therefor. The filling device according to the invention comprises: —a main frame (14) provided with an elevator conveyor (4) with a supply side (10) and a filling side (12); —a distributing device (28) connected operatively to the filling side of the elevator conveyor and provided with one or more distributors configured to distribute products over the holder; —height adjusting means (42,44) configured to move the distributing device in the height relative to the holder such that the distributing device is movable in the height during filling of the holder; and—a supply side guide arranged (66,68,70) on the main frame (14) for operation with the height adjusting means and configured to align the supply side of the elevator conveyor with a delivery end of a feed conveyor during a movement of the distributing device in the height.Type: GrantFiled: May 19, 2016Date of Patent: May 17, 2022Assignee: DE GREEF'S WAGEN-, CARROSSERIE- EN MACHINEBOUW B.VInventors: Wilhelm Jan Nijland, Hendrik Jan Van Ooijen, Harm-Jan De Bruin
-
Patent number: 11306360Abstract: The present application mainly relates to specific methods for inferring activity of a cellular signaling pathway in tissue and/or cells of a medical subject based at least on expression levels of one or more target gene(s) of the cellular signaling pathway measured in an extracted sample of the tissue and/or cells of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.Type: GrantFiled: December 18, 2013Date of Patent: April 19, 2022Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Hendrik Jan Van Ooijen, Wilhelmus Franciscus Johannes Verhaegh, Paul Arnold Van De Wiel
-
Patent number: 11309059Abstract: A method for determining a risk score that indicates a risk that a clinical event will occur within a certain period of time. The risk score is based at least in part on a combination of inferred activities of two or more cellular signaling pathways in a tissue and/or cells and/or a body fluid of a subject. The cellular signaling pathways comprise a Wnt pathway, an ER pathway, an HH pathway, and/or an AR pathway. The risk score is defined such that the indicated risk that the clinical event will occur within the certain period of time decreases with an increasing PER and increases with an increasing max(PWnt, PHH), wherein PER, PWnt, and PHH denote the inferred activity of the ER pathway, the Wnt pathway, and the HH pathway, respectively.Type: GrantFiled: April 24, 2014Date of Patent: April 19, 2022Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Wilhelmus Franciscus Johannes Verhaegh, Hendrik Jan Van Ooijen, Anja Van De Stolpe, Marcia Alves De Inda
-
Publication number: 20220057414Abstract: The present invention relates to device for determining a fibrinogen level in a sample comprising, a first input for obtaining an attenuance signal over time indicative of a fibrin polymerization of said sample, a second input for obtaining a reactant concentration signal over time indicative of a reactant concentration in said sample, wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit running a model using the reactant concentration signal as an input to provide a simulated attenuance signal over time, and an evaluation unit configured to infer the fibrinogen level of said sample by comparing the attenuance signal over time with the simulated attenuance signal over time.Type: ApplicationFiled: November 8, 2021Publication date: February 24, 2022Inventors: Hendrik Jan van Ooijen, Bart Jacob Bakker, René van den Ham
-
Patent number: 11169161Abstract: The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.Type: GrantFiled: December 17, 2015Date of Patent: November 9, 2021Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Hendrik Jan van Ooijen, Bart Jacob Bakker, René van den Ham
-
Publication number: 20200161006Abstract: The invention relates to a method for predicting a value of a parameter of a system (20). The value of the parameter of the system (20) is predicted by incrementally optimizing a pharmacokinetic and pharmacodynamic model based on values of parameters of the system (20) received over time. This allows for predicting values of the parameters of the system (20) with improved accuracy. In one embodiment the system (20) comprises a coagulation system (21) comprising an anticoagulant. The predicted value of the parameter of the system (20) can be a point in time at which the coagulation system (21) reaches hemostatic balance after a periodic supply of anticoagulant to the coagulation system (21) is discontinued.Type: ApplicationFiled: June 28, 2018Publication date: May 21, 2020Inventors: HENDRIK JAN VAN OOIJEN, BART JACOB BAKKER, RENE VAN DEN HAM
-
Publication number: 20200118649Abstract: The present invention relates to a method for estimating a value of a parameter of a blood coagulation system in a subject that is periodically supplied with an anticoagulant, wherein the parameter of the coagulation system is a time taken for the coagulation system to reach a state of coagulation after periodic supply of anticoagulant to the subject is discontinued. The value of the parameter of the coagulation system is estimated based on concentration levels of 5 or 6 coagulation proteins derived from the coagulation system at a predetermined point in time relative to a point in time of supply of a last dose of anticoagulant to the coagulation system. In one embodiment the 5 coagulation proteins are coagulation factor VII (F7), coagulation factor IX (F9), Anti-thrombin (AT), coagulation factor X (F10), and coagulation factor VIII (F8). Optionally the 6th coagulation protein is coagulation factor XI (F11).Type: ApplicationFiled: June 26, 2018Publication date: April 16, 2020Inventors: BART JACOB BAKKER, HENDRIK JAN VAN OOIJEN, RENE VAN DEN HAM
-
Publication number: 20190376142Abstract: The present invention relates to certain target genes of the FOXO transcription factor family, which are markers for an oxidative stress state and can be used for inferring an oxidative stress state of a FOXO transcription factor element in the body of a medical subject. The invention further relates to methods for inferring an oxidative stress state of a FOXO transcription element and for inferring the activity of the FOXO/PI3K cellular signalling pathway based on expression levels of the target genes as well as products to perform the methods.Type: ApplicationFiled: November 24, 2017Publication date: December 12, 2019Applicant: KONINKLIJKE PHILIPS N.V.Inventors: Anja VAN DE STOLPE, Rick VELTER, Wilhelmus Franciscus Johannes VERHAEGH, Hendrik Jan VAN OOIJEN, Martijn Theodorus Lambert AKSE
-
Patent number: 10138011Abstract: A filling device and method for filling a container with floating and/or suspended products, in particular for apples and pears. The device has a frame provided with a supply tank fillable with aqueous liquid, and a vacuum chamber for realizing an underpressure in at least a part of the supply tank; immersion means operatively connected to the frame for the purpose of placing the container into or removing the container from the supply tank; and feeder for feeding to the supply tank the aqueous liquid in which the floating and/or suspended products are entrainable. The feeder includes a flow tube or flow channel with which the floating and/or suspended products are carriable into the vacuum chamber.Type: GrantFiled: September 2, 2014Date of Patent: November 27, 2018Assignee: De Greef's Wagen-, Carrosserie-en Machinebouw B.V.Inventors: Hendrik Krijn Ruissen, Arjen Johannes Wilhelmus Van Kleef, Hendrik Jan Van Ooijen
-
Publication number: 20180271438Abstract: A bioinformatics process which provides an improved means to detect TGF-? cellular signaling pathway in a subject, such as a human, based on the expression levels of one or more unique target gene(s) of the TGF-? cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of TGF-? cellular signaling pathway target genes.Type: ApplicationFiled: June 7, 2018Publication date: September 27, 2018Inventors: HENDRIK JAN VAN OOIJEN, ANJA VAN DE STOLPE, DIANNE ARNOLDINA MARGARETHA WILHELMINA VAN STRIJP